Rtw Biotech Regulatory News (RTW)

 3 February 2020

RTW VENTURE FUND LIMITED(the "Company")

TOTAL VOTING RIGHTS

In accordance with DTR 5.6.1R, as at 31 January 2020 the Company had 169,753,087 Ordinary Shares in issue, each with equal voting rights, and no shares held in Treasury.

This total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota

Julia Enright

Barclays +44 (0)20 7623 2323Tom Swerling

Ben Newmark

Ryan McCarthy

J.P. Morgan Cazenove +44 (0)20 7742 4000William Simmonds

Ed Murray

Oliver Kenyon

James Bouverat (Sales)

Eddie Nissen (Sales)

Brunswick +44 (0)20 7404 5959Charis Gresser

Simone Selzer

About RTW Venture Fund Limited ("RTW"):

RTW is a listed medical sciences investment company with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.

The Company is externally managed by RTW Investments LP, its Alternative Investment Fund Manager.

Visit the RTW website at www.rtwfunds.com for more information.